C. Loirat, F. Fakhouri, and G. Ariceta, An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr Nephrol, vol.31, pp.15-39, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02149335

V. Fremeaux-bacchi, F. Fakhouri, and A. Garnier, Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-62, 2013.

M. Noris, J. Caprioli, and E. Bresin, Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-59, 2010.

S. Fischer, M. Huemer, and M. Baumgartner, Clinical presentation and outcome in a series of 88 patients with the cblC defect, J Inherit Metab Dis, vol.37, pp.831-871, 2014.

M. Huemer, S. Scholl-burgi, and K. Hadaya, Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy, Orphanet J Rare Dis, vol.9, p.161, 2014.

M. Lemaire, V. Fremeaux-bacchi, and F. Schaefer, Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, vol.45, pp.531-567, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01064383

R. Pai, M. R. Moore, T. Pilishvili, R. E. Gertz, C. G. Whitney et al., Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States, J Infect Dis, vol.192, pp.1988-95, 2005.

A. F. Veesenmeyer and M. B. Edmonson, Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome, Pediatr Infect Dis J, vol.32, pp.731-766, 2013.

R. Banerjee, A. L. Hersh, and J. Newland, Streptococcus pneumoniaeassociated hemolytic uremic syndrome among children in North America, Pediatr Infect Dis J, vol.30, pp.736-775, 2011.

K. L. Ong, M. Apostal, and N. Comstock, Strategies for surveillance of pediatric hemolytic uremic syndrome: Foodborne Diseases Active Surveillance Network (FoodNet), Clin Infect Dis, vol.54, issue.5, pp.424-455, 2000.

M. Bruyand, P. Mariani-kurkdjian, M. Gouali, D. Van-cauteren, and H. De-valk, Surveillance du syndrome hémolytique et urémique post-diarrhéique chez l'enfant de moins de 15 ans en France en, 2014.

G. Ardissino, S. Salardi, and E. Colombo, Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network, Eur J Pediatr, vol.175, pp.465-73, 2016.

M. Guirro, R. M. Piazza, R. L. De-souza, and B. E. Guth, Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls, BMC Infect Dis, vol.14, p.320, 2014.

M. Rivas, I. Chinen, E. Miliwebsky, and M. Masana, Risk factors for Shiga toxin-producing Escherichia coli-associated human diseases, Microbiol Spectr, vol.2, 2014.

C. Frank, D. Werber, and J. P. Cramer, Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany, N Engl J Med, vol.365, pp.1771-80, 2011.

U. Buchholz, H. Bernard, and D. Werber, German outbreak of Escherichia coli O104:H4 associated with sprouts, N Engl J Med, vol.365, pp.1763-70, 2011.

L. H. Gould, R. K. Mody, and K. L. Ong, Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: epidemiologic features and comparison with E. coli O157 infections, Foodborne Pathog Dis, vol.10, pp.453-60, 2013.

, Annual epidemiological report 2014-food-and waterborne diseases and zoonoses. Shiga toxin/verocytotoxin-producing Escherichia coli infection, 2014.

N. S. Sheerin, D. Kavanagh, T. H. Goodship, and S. Johnson, A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience, JM, vol.109, pp.27-33, 2016.

S. Johnson, J. Stojanovic, and G. Ariceta, An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome, Pediatr Nephrol, vol.29, pp.1967-78, 2014.

T. N. Petruzziello-pellegrini, D. A. Yuen, and A. V. Page, The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice, J Clin Invest, vol.122, pp.759-76, 2012.

M. Morigi, M. Galbusera, and S. Gastoldi, Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis, J Immunol, vol.187, pp.172-80, 2011.

J. M. Spinale, R. L. Ruebner, B. S. Kaplan, and L. Copelovitch, Update on Streptococcus pneumoniae associated hemolytic uremic syndrome, Curr Opin Pediatr, vol.25, pp.203-211, 2013.

C. Loirat, J. Saland, and M. Bitzan, Management of hemolytic uremic syndrome, Presse Med, vol.41, pp.115-150, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02149335

S. Bruneau, M. Neel, and L. T. Roumenina, Loss of DGK? induces endothelial cell activation and death independently of complement activation, Blood, vol.125, pp.1038-1084, 2015.

D. Martinelli, F. Deodato, and C. Dionisi-vici, Cobalamin C defect: natural history, pathophysiology, and treatment, J Inherit Metab Dis, vol.34, pp.127-162, 2011.

A. Undas, J. Brozek, and A. Szczeklik, Homocysteine and thrombosis: from basic science to clinical evidence, Thromb Haemost, vol.94, pp.907-922, 2005.

M. T. Geraghty, E. J. Perlman, and L. S. Martin, Cobalamin C defect associated with hemolytic-uremic syndrome, J Pediatr, vol.120, pp.934-971, 1992.

J. C. Tsai, M. A. Perrella, and M. Yoshizumi, Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis, Proc Natl Acad Sci, vol.91, pp.6369-73, 1994.

V. Fremeaux-bacchi, E. C. Miller, and M. K. Liszewski, Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome, Blood, vol.112, pp.4948-52, 2008.

J. E. Goicoechea-de, C. L. Harris, and J. Esparza-gordillo, Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome, Proc Natl Acad Sci, vol.104, pp.240-285, 2007.

M. Noris and G. Remuzzi, Atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.1676-87, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01793663

K. Lechner and H. L. Obermeier, Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases, Medicine, vol.91, pp.195-205, 2012.

J. M. Morton and J. N. George, Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer, J Oncol Pract, vol.12, pp.523-553, 2016.

G. A. Favre, M. Touzot, and V. Fremeaux-bacchi, Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome, Br J Haematol, vol.166, pp.802-807, 2014.

V. Eremina, J. A. Jefferson, and J. Kowalewska, VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, vol.358, pp.1129-1165, 2008.

A. Ustwani, O. Lohr, J. Dy, and G. , Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review, J Gastrointest Oncol, vol.5, pp.30-33, 2014.

S. Faguer, A. Huart, V. Fremeaux-bacchi, D. Ribes, and D. Chauveau, Eculizumab and drug-induced haemolytic-uraemic syndrome, Clin Kidney J, vol.6, pp.484-85, 2013.

Z. L. Al-nouri, J. A. Reese, D. R. Terrell, S. K. Vesely, and J. N. George, Drug-induced thrombotic microangiopathy: a systematic review of published reports, Blood, vol.125, pp.616-634, 2015.

J. A. Reese, D. W. Bougie, and B. R. Curtis, Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin, Am J Hematol, vol.90, pp.406-416, 2015.

J. N. George, Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder, Bone Marrow Transplant, vol.41, pp.917-935, 2008.

S. Jodele, B. L. Laskin, and C. E. Dandoy, A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury, Blood Rev, vol.29, pp.191-204, 2015.

A. S. Daly, A. Xenocostas, and J. H. Lipton, Transplantation-associated thrombotic microangiopathy: twenty-two years later, Bone Marrow Transplant, vol.30, pp.709-724, 2002.

G. A. Kennedy, N. Kearey, S. Bleakley, J. Butler, K. Mudie et al., Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange, Bone Marrow Transplant, vol.45, pp.699-704, 2010.

S. Jodele, C. Licht, and J. Goebel, Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy, Blood, vol.122, pp.2003-2010, 2013.

S. Jodele, K. Zhang, and F. Zou, The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy, Blood, vol.127, pp.989-96, 2016.

B. L. Laskin, J. Maisel, and J. Goebel, Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Transplantation, vol.96, pp.217-240, 2013.

F. S. De-fontbrune, C. Galambrun, and A. Sirvent, Use of Eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC, Transplantation, vol.99, pp.1953-59, 2015.

S. Jodele, T. Fukuda, and A. Vinks, Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Biol Blood Marrow Transplant, vol.20, pp.518-543, 2014.

L. Quintrec, M. Lionet, A. Kamar, and N. , Complement mutationassociated de novo thrombotic microangiopathy following kidney transplantation, Am J Transplant, vol.8, pp.1694-701, 2008.

K. Safa, M. S. Logan, I. Batal, S. Gabardi, H. G. Rennke et al., Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report, Clin Nephrol, vol.83, pp.125-154, 2015.

S. Chandran, L. Baxter-lowe, J. L. Olson, S. J. Tomlanovich, and A. Webber, Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report, Transplant Proc, vol.43, pp.2097-101, 2011.

C. H. Wilson, A. L. Brown, S. A. White, T. H. Goodship, N. S. Sheerin et al., Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab, Transplantation, vol.92, pp.42-43, 2011.

C. Gervasoni, A. L. Ridolfo, and M. Vaccarezza, Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy, Clin Infect Dis, vol.35, pp.1534-1574, 2002.

J. N. George, D. R. Terrell, S. K. Vesely, K. Hovinga, J. A. Lammle et al., Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer, Presse Med, vol.41, pp.177-88, 2012.

J. P. Rerolle, G. Canaud, and F. Fakhouri, Thrombotic microangiopathy and hypothermia in an HIV-positive patient: importance of cytomegalovirus infection, Scand J Infect Dis, vol.36, pp.234-271, 2004.

A. Belford, O. Myles, A. Magill, J. Wang, R. C. Myhand et al., Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation, Am J Hematol, vol.76, pp.156-62, 2004.

J. S. Chua, H. J. Baelde, and M. Zandbergen, Complement factor C4d is a common denominator in thrombotic microangiopathy, J Am Soc Nephrol, vol.26, pp.2239-2286, 2015.

E. Descombes, D. Droz, L. Drouet, J. P. Grunfeld, and P. Lesavre, Renal vascular lesions in lupus nephritis, Medicine, vol.76, pp.355-68, 1997.

A. El-husseini, S. Hannan, A. Awad, S. Jennings, V. Cornea et al., Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab, Am J Kidney Dis, vol.65, pp.127-157, 2015.

R. Coppo, L. Peruzzi, and A. Amore, Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy, Pediatr Nephrol, vol.30, pp.167-72, 2015.

B. Giannakopoulos and S. A. Krilis, The pathogenesis of the antiphospholipid syndrome, N Engl J Med, vol.368, pp.1033-1077, 2013.

G. Girardi, J. Berman, and P. Redecha, Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome, J Clin Invest, vol.112, pp.1644-54, 2003.

P. Redecha, R. Tilley, and M. Tencati, Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury, Blood, vol.110, pp.2423-2454, 2007.

K. Gropp, N. Weber, and M. Reuter, )-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator, Blood, vol.118, issue.2, pp.2774-83, 2011.

T. A. Zikos, J. Sokolove, N. Ahuja, and C. Berube, Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome, J Clin Rheumatol, vol.21, pp.311-324, 2015.

A. Kronbichler, R. Frank, and M. Kirschfink, Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report, Medicine, vol.93, p.143, 2014.

O. Bakhtar, B. Thajudeen, and B. L. Braunhut, A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab, Transplantation, vol.98, pp.17-18, 2014.

G. Couvrat-desvergnes, A. Masseau, and O. Benveniste, The spectrum of renal involvement in patients with inflammatory myopathies, Medicine, vol.93, pp.33-41, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01859438

A. Servais, L. H. Noel, and L. T. Roumenina, Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, pp.454-64, 2012.

L. Manenti, A. Vaglio, and E. Gnappi, Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis, Clin J Am Soc Nephrol, vol.10, pp.2143-51, 2015.

F. Fakhouri, L. Roumenina, and F. Provot, Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, pp.859-67, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00512540

G. Ardissino, W. Ossola, M. Baffero, G. M. Rigotti, A. Cugno et al., Eculizumab for atypical hemolytic uremic syndrome in pregnancy, Obstet Gynecol, vol.122, pp.487-89, 2013.

D. Sousa-amorim, E. Blasco, M. Quintana, L. Sole, M. De-cordoba et al., Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management, J Nephrol, vol.28, pp.641-686, 2015.

H. Zeisler, E. Llurba, and F. Chantraine, Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia, N Engl J Med, vol.374, pp.13-22, 2016.

F. Crovetto, N. Borsa, and B. Acaia, The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome, J Matern Fetal Neonatal Med, vol.25, pp.2322-2347, 2012.

J. E. Salmon, C. Heuser, and M. Triebwasser, Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort, PLoS Med, vol.8, p.1001013, 2011.

M. Frimat, M. Decambron, and C. Lebas, Renal cortical necrosis in postpartum hemorrhage: a case series, Am J Kidney Dis, vol.68, pp.50-57, 2016.

J. Zhu, M. Chaki, and D. Lu, Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production, Am J Physiol Renal Physiol, vol.310, pp.895-908, 2016.

F. Ozaltin, B. Li, and A. Rauhauser, DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN, J Am Soc Nephrol, vol.24, pp.377-84, 2013.

M. Locatelli, S. Buelli, and A. Pezzotta, Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement, J Am Soc Nephrol, vol.25, pp.1786-98, 2014.

E. Bresin, E. Rurali, and J. Caprioli, Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype, J Am Soc Nephrol, vol.24, pp.475-86, 2013.

E. Rodriguez, P. M. Rallapalli, A. J. Osborne, and S. J. Perkins, New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3, Biosci Rep, vol.34, p.146, 2014.

M. Lek, K. J. Karczewski, and E. V. Minikel, Analysis of protein-coding genetic variation in 60,706 humans, Nature, vol.536, pp.285-91, 2016.

S. Richards, N. Aziz, and S. Bale, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, vol.17, pp.405-429, 2015.

M. Delvaeye, M. Noris, D. Vriese, and A. , Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.345-57, 2009.

F. Bu, T. Maga, and N. C. Meyer, Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.25, pp.55-64, 2014.

A. Rosales, J. Hofer, and L. B. Zimmerhackl, Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae, Clin Infect Dis, vol.54, pp.1413-1434, 2012.

R. K. Mody, W. Gu, and P. M. Griffin, Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death, J Pediatr, vol.166, pp.1022-1051, 2015.

J. M. Spinale, R. L. Ruebner, L. Copelovitch, and B. S. Kaplan, Long-term outcomes of Shiga toxin hemolytic uremic syndrome, Pediatr Nephrol, vol.28, pp.2097-105, 2013.

C. Chiurchiu, A. Firrincieli, M. Santostefano, M. Fusaroli, G. Remuzzi et al., Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection, Am J Kidney Dis, vol.41, p.4, 2003.

P. Coppo, M. Schwarzinger, and M. Buffet, Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience, PLoS One, vol.5, p.10208, 2010.

F. Fakhouri, Y. Delmas, and F. Provot, Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases, Am J Kidney Dis, vol.63, pp.40-48, 2014.

R. O. Mathew, A. Nayer, and A. Asif, The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy, J Am Soc Hypertens, vol.10, pp.352-59, 2015.

S. Nathanson, T. Kwon, and M. Elmaleh, Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.5, pp.1218-1246, 2010.

T. Magnus, J. Rother, and O. Simova, The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak, Brain, vol.135, pp.1850-59, 2012.

A. M. Durkan, S. Kim, J. Craig, and E. Elliott, The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study, Arch Dis Child, vol.101, pp.387-91, 2016.

M. Malina, A. Gulati, A. Bagga, M. A. Majid, E. Simkova et al., Peripheral gangrene in children with atypical hemolytic uremic syndrome, Pediatrics, vol.131, pp.331-366, 2013.

C. Rigothier, Y. Delmas, and L. T. Roumenina, Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgA? antibody, Am J Kidney Dis, vol.66, pp.331-367, 2015.

G. Ardissino, F. Tel, and S. Testa, Skin involvement in atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.63, pp.652-55, 2014.

M. A. Dragon-durey, S. K. Sethi, and A. Bagga, Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, vol.21, pp.2180-87, 2010.

M. Noris and G. Remuzzi, Cardiovascular complications in atypical haemolytic uraemic syndrome, Nat Rev Nephrol, vol.10, pp.174-80, 2014.

H. Hu, A. Nagra, M. R. Haq, and R. D. Gilbert, Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement, Pediatr Nephrol, vol.29, pp.1103-1109, 2014.

K. Emirova, E. Volokhina, E. Tolstova, and B. Van-den-heuvel, Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab, BMJ Case Rep, 2016.

K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata, FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay, Br J Haematol, vol.129, pp.93-100, 2005.

R. K. Mody, R. E. Luna-gierke, and T. F. Jones, Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli, Arch Pediatr Adolesc Med, vol.166, pp.902-911, 2012.

T. J. Dallman, L. Byrne, N. Launders, K. Glen, K. A. Grant et al., The utility and public health implications of PCR and whole genome sequencing for the detection and investigation of an outbreak of Shiga toxin-producing Escherichia coli serogroup O26:H11, Epidemiol Infect, vol.143, pp.1672-80, 2015.

M. Scully and T. Goodship, How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome

, Br J Haematol, vol.164, pp.759-66, 2014.

J. Zuber, F. Fakhouri, L. T. Roumenina, C. Loirat, and V. Fremeaux-bacchi, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-57, 2012.

J. C. Koenig, F. Rutsch, and C. Bockmeyer, Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency, Pediatr Nephrol, vol.30, pp.1203-1209, 2015.

C. Gall, E. Delmas, Y. , D. Parscau, and L. , Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency, Am J Kidney Dis, vol.63, pp.119-142, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01011789

S. Grange, S. Bekri, and E. Artaud-macari, Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency, Lancet, vol.386, pp.1011-1023, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01850500

J. N. George, Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised?, Lancet, vol.386, p.1012, 2015.

S. R. Cataland, V. M. Holers, S. Geyer, S. Yang, and H. M. Wu, Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP, Blood, vol.123, pp.3733-3771, 2014.

M. Noris, M. Galbusera, and S. Gastoldi, Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, pp.1715-1741, 2014.

F. Bu, N. C. Meyer, and Y. Zhang, Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.65, pp.968-69, 2015.

E. Gavriilaki, X. Yuan, and Z. Ye, Modified Ham test for atypical hemolytic uremic syndrome, Blood, vol.125, pp.3637-3683, 2015.

L. H. Gould, L. Demma, and T. F. Jones, Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, Clin Infect Dis, vol.49, pp.1480-85, 2000.

G. Ardissino, V. Dacco, and S. Testa, Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome, Pediatr Nephrol, vol.30, pp.345-52, 2015.

G. Ardissino, F. Tel, and I. Possenti, Early volume expansion and outcomes of hemolytic uremic syndrome, Pediatrics, vol.137, pp.1-9, 2016.

N. Safdar, A. Said, R. E. Gangnon, and D. G. Maki, Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis, JAMA, vol.288, pp.996-1001, 2002.

S. B. Freedman, J. Xie, M. S. Neufeld, W. L. Hamilton, L. Hartling et al., Shiga toxin-producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis, Clin Infect Dis, vol.62, pp.1251-58, 2016.

J. Menne, M. Nitschke, and R. Stingele, Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study, BMJ, vol.345, p.4565, 2012.

C. S. Wong, J. C. Mooney, and J. R. Brandt, Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis, Clin Infect Dis, vol.55, pp.33-41, 2012.

K. E. Smith, P. R. Wilker, P. L. Reiter, E. B. Hedican, J. B. Bender et al., Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Pediatr Infect Dis J, vol.31, pp.37-41, 2012.

M. Nitschke, F. Sayk, and C. Hartel, Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4, JAMA, vol.307, pp.1046-52, 2012.

R. P. Vonberg, M. Hohle, and M. Aepfelbacher, Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study, Clin Infect Dis, vol.56, pp.1132-1172, 2013.

M. Agger, F. Scheutz, S. Villumsen, K. Molbak, and A. M. Petersen, Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal, J Antimicrob Chemother, vol.70, pp.2440-2486, 2015.

S. Loos, T. Ahlenstiel, and B. Kranz, An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children, Clin Infect Dis, vol.55, pp.753-59, 2012.

J. T. Kielstein, G. Beutel, and S. Fleig, Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry, Nephrol Dial Transplant, vol.27, pp.3807-3822, 2012.

A. Greinacher, S. Friesecke, and P. Abel, Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial, Lancet, vol.378, pp.1166-73, 2011.

C. Combe, H. N. Bui, V. De-precigout, G. Hilbert, and Y. Delmas, Immunoadsorption in patients with haemolytic uraemic syndrome, Lancet, vol.379, pp.517-535, 2012.

, Immunoadsorption in patients with haemolytic uraemic syndrome-Authors' reply, Lancet, vol.379, pp.518-537, 2012.

A. R. Melton-celsa, O. 'brien, and A. D. , New therapeutic developments against Shiga toxin-producing Escherichia coli, Microbiol Spectr, vol.2, 2014.

A. L. Lapeyraque, M. Malina, and V. Fremeaux-bacchi, Eculizumab in severe Shiga-toxin-associated HUS, N Engl J Med, vol.364, pp.2561-63, 2011.

Y. Delmas, B. Vendrely, and B. Clouzeau, Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab, Nephrol Dial Transplant, vol.29, pp.565-72, 2014.

A. Saini, A. R. Emke, M. C. Silva, and S. J. Perlman, Response to eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations, Clin Pediatr, vol.54, pp.387-89, 2015.

L. Pape, H. Hartmann, F. C. Bange, S. Suerbaum, E. Bueltmann et al., Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement, Medicine, vol.94, p.1000, 2015.

L. A. Greenbaum, M. Fila, and G. Ardissino, Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome, Kidney Int, vol.89, pp.701-712, 2016.

L. Rees, L. A. Greenbaum, and M. Fila, A prospective study of paediatric patients with atypical hemolytic uremic syndrome treated with eculizumab: 1-year update (abstract), Pediatr Nephrol, vol.30, p.1564, 2015.

C. M. Legendre, C. Licht, and P. Muus, Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, vol.368, pp.2169-81, 2013.

C. Licht, L. A. Greenbaum, and P. Muus, Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, vol.87, pp.1061-73, 2015.

F. Fakhouri, M. Hourmant, and J. M. Campistol, Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial, Am J Kidney Dis, vol.68, pp.84-93, 2016.

F. Fakhouri, M. Hourmant, and J. M. Campistol, Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-year update, J Am Soc Nephrol, vol.25, p.751, 2014.

R. Cofiell, A. Kukreja, and K. Bedard, Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS, Blood, vol.125, pp.3253-62, 2015.

E. Gomez-cibeira, Y. Ivanovic-barbeito, and E. Gutierrez-martinez, Eculizumab-related progressive multifocal leukoencephalopathy, Neurology, vol.86, pp.399-400, 2016.

J. V. Walle, Y. Delmas, G. Ardissino, J. Wang, J. F. Kincaid et al., Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment, J Nephrol, 2016.

N. Ito, H. Hataya, and K. Saida, Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan, Clin Exp Nephrol, vol.20, pp.265-72, 2015.

A. Avila, B. Vizcaino, P. Molina, E. Gavela, M. Perez-ebri et al., Remission of aHUS neurological damage with eculizumab, Clin Kidney J, vol.8, pp.232-268, 2015.

E. Baskin, K. Gulleroglu, A. Kantar, U. Bayrakci, and O. Ozkaya, Success of eculizumab in the treatment of atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.30, pp.783-89, 2015.

G. T. Greenwood, Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab, Int Med Case Rep J, vol.8, pp.235-274, 2015.

M. Cugno, R. Gualtierotti, and I. Possenti, Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome, J Thromb Haemost, vol.12, pp.1440-1448, 2014.

M. J. Walport, Complement. First of two parts, N Engl J Med, vol.344, pp.1058-66, 2001.

M. Hisano, A. Ashida, and E. Nakano, Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy, Pediatr Int, vol.57, pp.313-330, 2015.

D. Noone, A. Waters, and F. G. Pluthero, Successful treatment of DEAP-HUS with eculizumab, Pediatr Nephrol, vol.29, pp.841-51, 2014.

H. Green, E. Harari, and M. Davidovits, Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab, Ren Fail, vol.36, pp.1119-1140, 2014.

D. Chiodini, B. Davin, J. C. Corazza, and F. , Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome, Pediatrics, vol.133, pp.1764-68, 2014.

S. Zschiedrich, E. P. Prager, and E. W. Kuehn, Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab, Ann Intern Med, vol.159, p.76, 2013.

G. Ardissino, W. Ossola, M. Baffero, G. M. Rigotti, A. Cugno et al., Eculizumab for atypical hemolytic uremic syndrome in pregnancy, Obstet Gynecol, vol.122, pp.487-89, 2012.

R. J. Kelly, B. Hochsmann, and J. Szer, Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria, N Engl J Med, vol.373, pp.1032-1071, 2015.

L. Quintrec, M. Zuber, J. Moulin, and B. , Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome, Am J Transplant, vol.13, pp.663-75, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00945715